Missing HLA C Group 1 Ligands in Patients with AML and MDS Is Associated with Reduced Risk of Relapse and Improved Survival after Allogeneic STEM CELL Transplantation (SCT) with Fludarabine and Treosulfan Reduced Toxicity Conditioning  by Shimoni, Avichai et al.
Abstracts / Biol Blood Marrow Transplant 20 (2014) S257eS285S280Further investigation of intensiﬁed MMF dosing adjusted for
body weight with trough level monitoring for the prevention
of aGVHD in CBT recipients is strongly indicated.435
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Purpose: To determine the impact of Prosthetic Replacement
of the Ocular Surface Ecosystem (PROSE) treatment at ﬁve
years in patients with Ocular Graft versus Host Disease
(oGVHD).
Methods: All oGVHD patients seen in consultation for PROSE
treatment from 1/1/2008 e 6/30/2008 were identiﬁed
through billing records. Retrospective review of medical re-
cords, manufacturing data, and 5 year quality data was
undertaken.
Results: This 2008 oGVHD cohort was comprised of 21 pa-
tients. As of July 2013, the conclusion of the follow-up period,
6 patients were deceased and excluded from subsequent
analysis. One patient was not a candidate for PROSE treat-
ment due to not completing the training process, leaving 14
patients who were dispensed devices. After ﬁve years,
continued device wear was conﬁrmed in 10 of these 14 (71%)
patients. Discontinuation of wear was conﬁrmed in 3/14
(21%) patients. We could not ascertain wearing statusin the
remaining 1 (7%) patients. Likelihood of continued device
wear at ﬁve years is not dependent on age, sex, general
health status or proximity of residence to our clinic (p>0.05,
for each mean, by unpaired t-test). Reasons for discontinu-
ation of wear are reported. NEI VFQ-25 composite score
increased for patients wearing PROSE devices at 6 months
(D¼+26 points, p<0.001, mean¼85) with no signiﬁcant
decline after ﬁve years (D ¼-3 points, p¼0.73).
Conclusions: PROSE treatment offers continued beneﬁt, as
deﬁned by continued device wear and visual functioning at 5
years, to the majority of oGVHD candidates who were
dispensed devices. PROSE treatment is characterized by
long-term success in the management of Ocular Graft Versus
Host Disease.436
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Background: Sclerodermatous GVHD (sclerosis) is seen in
approximately 20% of patients who received initial systemic
treatment for chronic GVHD after allogeneic HCT (Inamoto et
al. Blood 2013). Published reports suggest up regulation ofPDGFR (platelet derived growth factor receptor) and TGF-b
(transforming growth factor-b) pathways in patients with
sclerosis. Both pathways are subject to inhibition by imatinib.
We probed our database to explore if TKI use post HCT, will
reduce the incidence of sclerosis in patients with CML and
Ph+ALL.
Methods: Eighty-nine consecutive patients with CML (n¼41)
or Ph+ALL (n¼48) who underwent allogeneic HCT between
2005 to 2010 were included for analysis. Average age for
transplant was 44 years (range 18-62) All patients received
GCSF-mobilized PBSC from sibling (n¼49) or unrelated do-
nors (n¼40). A majority of our patients (n¼74) received fully
myeloablative conditioning regimens (FTBI with Cytoxan or
VP-16: n¼56, TMLI based regimens n¼3, and Bu/Cy: n¼15)
while the remaining 15 patients received reduced intensity
conditioning (Flu/Mel: n¼14, Clo/Mel: n¼1). Post transplant
GVHD prophylaxis was with sirolimus/tacrolimus in 53
(60%), tacrolimus/MTX in 13 (15%), and tacrolimus/sirolimus/
MTX in 11 (12%) patients. Median follow up duration was 30
months (Range 0.03-84.8 months).
Results: 55 patients (62%) received TKI therapy post trans-
plant while 34 patients (38%) did not receive TKI due to-
cytopenias (45%), TKI intolerance or resistance (27%), GVHD
(9%), infections (6%), and/or LFT abnormalities (6%). Median
time to start TKI post-transplant was 1.9 months (range: 0.7
e 17.9 months). The median duration of TKI therapy was 9.1
months (range 0.1- 89.4 months). Thirteen of 59 surviving
patients are currently on TKI therapy at last follow up.
The cumulative incidence of grade II-IV acute GVHD in
this patient cohort was 47% (Grade III/IV: 17%). The incidence
of chronic GVHD in the entire group was 76% (limited: n¼6,
extensive: n¼62). Eight of 55 patients exposed to TKI therapy
post transplant developed sclerosis with the median onset
time of 13.8 months (range 10.3-33.1 months). Sclerosis
occurred in 5 patients during TKI therapy whereas 3 patients
developed sclerosis after discontinuation of TKI. Seven of 34
patients who did not receive TKI post-HCT developed scle-
rosis with median onset of 17.1 months (range 6.7-53.7
months). The 2-year cumulative incidence of sclerosis was
9.2% (CI: 3.9-21.2%) for the TKI exposed group and 14.8% (CI:
6.6-33.4%) in the non-TKI group (p ¼0.69).
Conclusions: To our knowledge, this is the ﬁrst cohort study
to describe the incidence of sclerosis in patients who
received TKI post-HCT. The incidence of sclerosis appeared
consistent with the reported rate in the literature. At the
power for this analysis, statistical signiﬁcance- favoring TKI
use post HCT to reduce incidence of sclerotic cGVHD, was not
achieved.437
Missing HLA C Group 1 Ligands in Patients with AML and
MDS Is Associated with Reduced Risk of Relapse and
Improved Survival after Allogeneic STEM CELL
Transplantation (SCT) with Fludarabine and Treosulfan
Reduced Toxicity Conditioning
Avichai Shimoni 1, Massimo Bernardi 2, Ronit Yerushalmi 1,
Iacopo Peccatori 2, Noga Shem-Tov 1, Alessandro Lo Russo 2,
Yulia Volchek 1, Maria Chiara Bonini 3, Arnon Nagler 1,
Fabio Ciceri 2. 1 Division of Hematology and Bone Marrow
Transplantation, Chaim Sheba Medical Center, Tel-Hashomer,
Israel; 2 Hematology and Bone Marrow Transplantation Unit,
San Raffaele Scientiﬁc Institute, Milan, Italy; 3 Division
Regenerative Medicine, Stem Cells and Gene Therapy -
Experimental Hematology Unit, San Raffaele Scientiﬁc Institute,
Milan, Italy
Abstracts / Biol Blood Marrow Transplant 20 (2014) S257eS285 S281Allogeneic SCT is curative therapy in patients (pts) with AML/
MDS. Reduced toxicity conditioning with ﬂudarabine and
treosulfan (FT) is a dose intensive regimen with enhanced
anti leukemia effect and acceptable toxicity. However,
relapse after SCT remains the main obstacle to cure. Natural
killer (NK) cell alloreactivity has documented role in
reducing relapse after haploidentical SCT in AML but its role
in HLA matched SCT is more controversial. The missing
ligand theory suggests that missing KIR ligands in the
recipient may drive donor NK alloreactivity in the absence of
HLA mismatch. There is no data on NK cell role in treosulfan
based conditioning. Here we analyzed the prognostic factors
for relapse and overall survival (OS) in 203 pts with AML
(n¼129, 29 secondary) and MDS (n¼74) given SCT from
matched sibling (n¼97) or matched unrelated donors
(n¼106) using FT conditioning. Median age was 58 years
(21e76). Disease status was CR1 (n¼65), CR2/3 (n¼24), no CR
(n¼44) or previously untreated MDS (n¼70). 67% expressed
at least one Bw4 antigen, 81% expressed C group 1 alleles and
66% C group 2 alleles. With median follow-up of 48 months
(6-108) 86 pts are alive, 66 died of relapse and 51 of non-
relapse causes (NRM). 5-year OS and leukemia-free survival
(LFS) rates were 39% and 36%, respectively. 5-year cumula-
tive incidence of relapse and NRM was 38% and 27%,
respectively. The most signiﬁcant predictor of relapse was
disease status at SCT. 5-year relapse rates were 33% in CR/
untreated MDS and 55% in refractory disease (p¼0.001). Pts
expressing HLA C group 1alleles had a relapse rate of 45%
compared to 26% in pts with missing group 1 ligands
(p¼0.03). Missing HLA C group 2 or Bw4 ligands had no effect
on relapse. Multivariate analysis identiﬁed no CR at SCT (HR
3.6, p¼0.001), missing HLA C group 1 ligand (HR 2.6, p¼0.03),
sibling donor (HR 1.8, p¼0.04), poor cytogenetics (HR 1.7,
p¼0.05) and female donor to male recipient (HR 0.5, p¼0.06)
as independent factors predicting relapse. The reduced
relapse rate associated with missing HLA C group 1 ligand
was more pronounced in pts with MDS/ secondary AML, 39%
Vs 7%, respectively (p¼0.02) and in pts in untreated disease
or no CR, 46% Vs. 8%, respectively (p¼0.02). Missing HLA li-
gands were not associated with GVHD or NRM. LFS was 46%
in pts with missing HLA C group1 ligand compared to 30% in
pts expressing the ligand (p¼0.07). Multivariate analysis
identiﬁed SCT not in CR (HR 2.8, p¼0.0007), SCT comorbidity
score > 2 (HR 1.5, p¼0.06) and missing HLA C group 1 ligand
(HR 1.9, p¼0.02) as independent predicting factor for LFS. In
conclusion, missing HLA C group 1 ligand in SCT recipients
with AML/ MDSmay be associated with reduced relapse risk,
similar NRM and improved LFS possibly due to enhanced NK
alloreactivity. These observations merit further study in
larger cohorts and in pts given other conditioning regimens
to elucidate the potential role of treosulfan conditioning in
these ﬁndings.438
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Immune mediated demyelinating disease after allogeneic
stem cell transplantation is a rare entity with unclear etiol-
ogy. Acute inﬂammatory demyelinating polyneuropathy
(AIDP) has been reported post related and unrelated alloge-
neic stem cell transplantation but no such case has been
reported post unrelated cord blood transplantation. Wehereby present the ﬁrst case of GBS post double umbilical
cord blood transplantation (DUCBT).
A 55 year old male with relapsed refractory CLL received
DUCBT with two 5/6 matched cord units, with ﬂudarabine,
cytoxan and total body irradiation based intensity condi-
tioning regimen. GVHD prophylaxis was with cyclosporine
and mycophenolate. Patient developed grade 4 acute GVHD
of the gut with a complete resolution with steroid therapy. 7
months post transplantation, patient presented with skin
rash and tingling in both feet that progressed rapidly to
lower extremity paralysis over the course of 2 days. Physical
exam showed maculo-papular rash affecting his upper ex-
tremities, upper chest and back area. Neurologic exam was
signiﬁcant for motor weakness in lower extremities 2/5,
plantar ﬂexion and knee ﬂexion 3/5. He had loss of deep
tendon reﬂexes in both lower extremities (Achilles and
Patellar) and upper extremities (biceps and triceps). Workup
revealed normal blood counts, organ function, vitamin B12,
folate, TSH level, free cortisol. SPEP and immunﬁxation were
also normal. Magnetic resonance imaging of the CNS was
normal. Serology for Lyme disease, Epstein Bar virus (EBV),
syphilis, cytomegalo virus (CMV), Hepatitis, HIV, toxoplasma,
enterovirus and human herpes virus 6 was negative. Blood
tests for autoimmune markers including ANA, acetylcholine
esterase and volted calcium channel antibodies were normal.
A lumbar puncture showed high protein level of 67mg/dl, 1
nucleated cell/mm3 and normal glucose. CSF was negative
for oligoclonal bands, West Nile virus, cryptosporidium,
HHV6, HSV 1 and 2, gram stain and cultures. Nerve con-
duction studies and needle electormyegraphy were sugges-
tive of AIDP.
Based on the above workup, he was diagnosed with GBS and
started on therapy with intravenous immunoglobulin at
0.5gm/kg for 4 days and prednisone 1mg/kg daily for the
treatment of GVHD. Etiology of GBS was presumed to be
related to GVHD as his workup was negative for campylo-
bacter, HIV and CMV. He became ambulatory without assis-
tance in 4 weeks but his weakness symptoms relapsed with
prednisone was taper. Prednisone was increased again to
1mg/kg and sirolimus was started. Patient was successfully
tapered of prednisone and remains fully ambulatory without
assistance or evidence of GVHD on single agent sirolimus 16
months post DUCBT.
This is the ﬁrst case of autoimmune demyelinating poly-
neuropathy post DUCBT with association of GVHD that was
managed successfully with a combination of intravenous
immunoglobulins, steroids and sirolimus.439
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Rapamycin inhibits mTOR, a crucial immune regulator.
RAPA-conditioned DC (RAPA-DC) enrich for Treg and induce
alloreactive T cell apoptosis. They promote experimental
allograft survival, yet secrete increased IL-12, crucial for
generation of IFN-g+CD4+ T cells. IFN-g is also pro-apoptotic
and IL-12-driven IFN-g inhibits GVHD. We hypothesized that
IL-12hi RAPA-DCwould facilitate IFN-g-mediated alloreactive
